Status:
COMPLETED
A Phase IIa Study Assessing the Effects of AZD1236 on Biomarkers in Chronic Obstructive Pulmonary Disease (COPD) Patients
Lead Sponsor:
AstraZeneca
Conditions:
Chronic Obstructive Pulmonary Disease
Eligibility:
All Genders
40+ years
Phase:
PHASE2
Brief Summary
The primary aim of this study is to investigate the effects of AZD1236 compared with placebo ("inactive substance") in COPD patients by analysing biomarkers for inflammation and tissue degradation in ...
Eligibility Criteria
Inclusion
- Diagnosis of COPD for 1 month
- Men or postmenopausal women
- Spirometry values indicating symptomatic patients
- Smoking history equivalent to using 20 cigarettes a day for 10 years.
Exclusion
- Any current respiratory tract disorders other than COPD
- Requirement for regular oxygen therapy
- Acute worsening of COPD (exacerbation) 1,5 month prior to study drug administration
- Use of oral or parenteral glucocorticosteroids within 30 days and use of inhaled steroids 14 days prior to the study
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00758706
Start Date
September 1 2008
End Date
May 1 2009
Last Update
April 16 2015
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Aalborg, Denmark
2
Research Site
Arhus C, Denmark
3
Research Site
København NV, Denmark
4
Research Site
Odense C, Denmark